Z Forms A Phenoxy Alkyl Or Phenoxy Alkenyl Radical Patents (Class 514/543)
-
Publication number: 20110311625Abstract: An improved solid dosage form of fenofibrate which exhibits improved dissolution properties leading to increased bioavailability of fenofibrate. A novel core-shell approach to the composition is provided as well as a process for the preparation of the improved solid dosage forms.Type: ApplicationFiled: June 13, 2011Publication date: December 22, 2011Inventors: Amruth Gowda Doddaveerappa, Rajesh Jagannath Kasunde, Nagaprasad Vishnubhotla, Sivakumaran Meenakshisunderam
-
Publication number: 20110311619Abstract: The invention relates to a pharmaceutical formulation of nanonised fenofibrate, to a method for preparing same, and to the uses thereof.Type: ApplicationFiled: December 24, 2009Publication date: December 22, 2011Applicant: EthypharmInventors: Catherine Herry, Pascal Oury
-
Publication number: 20110311528Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, psoriasis.Type: ApplicationFiled: June 22, 2011Publication date: December 22, 2011Applicant: Action MedicinesInventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Publication number: 20110305733Abstract: The present invention relates to granulates comprising particles of metformin and particles of a fibrate. The invention further relates to pharmaceutical compositions containing such granulates. The invention also relates to processes for preparing said granulates and said pharmaceutical compositions.Type: ApplicationFiled: August 24, 2011Publication date: December 15, 2011Applicant: FOURNIER LABORATORIES IRELAND LIMITEDInventors: Gordon DAWSON, Leonard McCarthy
-
Publication number: 20110287066Abstract: Process for the production of nanoporous foamed active substance-containing preparations, wherein the active substance is present embedded in a pharmaceutically acceptable polymer, wherein, in stage a) loading of a polymeric molding composition or a polymer melt with a propellant is effected at a pressure and at a temperature at which the propellant is in the supercritical state, in stage b) heating of the laden polymer molding compound or melt is carried out under pressure at a temperature which lies in the range from ?40 to +60° C., preferably ?20 to +55° C., and especially preferably 0 to +50° C. around the glass transition temperature of the unladen (prior to loading) polymeric molding compound and in stage c) a depressurization of the polymeric molding compound or melt laden in stage a) and heated under pressure in stage b) is effected out with a depressurization rate in the range from 15,000 to 200,000 MPa/sec.Type: ApplicationFiled: May 20, 2011Publication date: November 24, 2011Applicant: BASF SEInventors: Jan Kurt Walter Sandler, Ingo Bellin, Dejan Djuric, Karl Kolter, Holger Ruckdäschel
-
Patent number: 8058308Abstract: The invention concerns novel substituted 1,3-diphenylprop-2-en-1-one derivatives, pharmaceutical compositions comprising same, their therapeutic uses, in particular for treating cerebral ischemia. The invention also concerns a method for preparing said derivatives.Type: GrantFiled: April 11, 2011Date of Patent: November 15, 2011Assignee: GenfitInventors: Jamila Najib, Karine Caumont-Bertrand
-
Patent number: 8058310Abstract: The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.Type: GrantFiled: February 25, 2010Date of Patent: November 15, 2011Assignees: University of South Florida, McGill University, The Hong Kong Polytechnic UniversityInventors: Q. Ping Dou, Tak-Hang Chan, David M. Smith
-
Publication number: 20110244002Abstract: The present invention encompasses formulations and methods for producing solid dispersions comprising mesoporous materials with poorly aqueous soluble active ingredients. The active ingredient is formed in the amorphous state and entrapped in the nanosized pores of the mesoporous excipients using a co-spray drying process. The pore walls of mesoporous channels stabilize the amorphous form of active ingredient against re-crystallization. The amorphous active ingredient entrapped in mesoporous channels exhibits good stability during extended storage under stress test conditions and possesses significantly enhanced dissolution rates.Type: ApplicationFiled: February 18, 2009Publication date: October 6, 2011Applicant: Agency for Science, Technology and ResearchInventors: Shou-Cang Shen, Wai Kiong Ng, Leonard Chia
-
Publication number: 20110245303Abstract: Described herein are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.Type: ApplicationFiled: October 7, 2009Publication date: October 6, 2011Applicant: Amira Pharmaceuticals, Inc.Inventors: John Howard Hutchinson, Thomas Jon Seiders, Jeannie M. Arruda, Jeffrey Roger Roppe
-
Publication number: 20110244032Abstract: Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic, or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.Type: ApplicationFiled: May 10, 2011Publication date: October 6, 2011Applicant: Jagotec AGInventors: Indu Parikh, Awadhesh K. Mishra, Robert Donga, Michael G. Vachon
-
Publication number: 20110237551Abstract: The invention relates to the use of para-coumaric acid or para-hydroxycinnamic acid derivatives in cosmetic or dermatological compositions, specifically to the use of at least one compound derived from para-coumaric acid having a general formula (I) below: in which, especially, Z represents an oxygen or an —NH— group; X and Y are identical and each represent a CH or CH2 group, as an active principle with depigmenting, free-radical-scavenging and/or antiinflammatory is activity. The invention also relates to the use of the above compounds for cosmetic care or for the preparation of a pharmaceutical composition, especially for depigmenting an area of skin, having antiradical and/or antiinflammatory activity.Type: ApplicationFiled: June 3, 2011Publication date: September 29, 2011Applicants: BASF Beauty Care Solutions France S.A.S., Universite Joseph Fourier-Grenoble 1Inventors: Sabrina Okombi, Delphine Rival, Ahcene Boumendjel, Anne-Marie Mariotte, Eric Perrier
-
Patent number: 8022105Abstract: Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.Type: GrantFiled: August 24, 2009Date of Patent: September 20, 2011Assignee: The Brigham and Women's Hospital, Inc.Inventor: Charles N. Serhan
-
Publication number: 20110224294Abstract: The invention relates to a compound represented by the following formula (I): and pharmaceutically acceptable salts, stereoisomers, enantiomers, prodrugs and solvates thereof. The compounds are useful as an agent for enhancing the neurite outgrowth and preventing or treating of diseases associated with HDAC in particular, tumor or cell proliferative diseases. In particular, the compounds of the invention can be used as an agent for anti-cancer, anti-diabetic, and anti-neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Spinocerebellar Ataxias (SCA), and human spinal muscular atrophy (SMA).Type: ApplicationFiled: May 24, 2011Publication date: September 15, 2011Applicant: NATUREWISE BIOTECH & MEDICALS CORPORATIONInventors: Chung-Yang Huang, Chia-Nan Chen, Wei-Jan Huang, Chia-Wei Lin, Jing-Shi Huang, Li-Ling Chi, Ai-Ling Chen, Chi-Yun Lee, Yu-Chen Huang
-
Publication number: 20110223244Abstract: Pharmaceutical formulations that resist ethanol-induced dose dumping and methods of use thereof.Type: ApplicationFiled: March 9, 2011Publication date: September 15, 2011Applicant: Elan Pharma International LimitedInventors: Gary Liversidge, David Manser, Hardik Shah, Stephen B. Ruddy, Gurvinder Singh Rekhi
-
Publication number: 20110217369Abstract: The present invention relates to a fenofibrate composition comprising: fenofibrate, a surfactant, a hydrophilic polymer and one or more anti-foaming agents. The invention also relates to a novel process for preparing said composition that has enhanced dissolution and absorption characteristics.Type: ApplicationFiled: September 3, 2010Publication date: September 8, 2011Applicant: RANBAXY LABORATORIES LIMITEDInventors: Amit Gupta, Nidhi Singh, Romi Barat Singh
-
Publication number: 20110217289Abstract: Formulations of sparingly water-soluble active ingredientscomprising carrier particles provided with active ingredient-containing coatings, the sparingly soluble active ingredients being embedded in coatings composed of amphiphilic copolymers, and the coatings being applied in the form of a solvent-free melt.Type: ApplicationFiled: March 4, 2011Publication date: September 8, 2011Applicant: BASF SEInventors: Karl Kolter, Dejan Djuric
-
Publication number: 20110212169Abstract: Disclosed are a method for preparing a powder containing a nanoparticulated sparingly soluble drug, a powder prepared thereby, and a pharmaceutical composition containing the same. The disclosed method includes: providing a uniformly dispersed solution of a sparingly soluble drug which is formed into nanoparticles in the presence of a surface stabilizer; mixing the uniformly dispersed solution with a water-soluble dispersant solution; and drying the mixed solution to obtain the powder. When the powder containing the nanoparticulated sparingly soluble drug obtained by the disclosed method is redispersed in an aqueous solution, the sparingly soluble drug retains a particle size in the nano scale while the solubility and the dissolution rate of the drug are increased, thereby providing enhanced bioavailability. Consequently, the present disclosure can be useful in the development of preparations of a sparingly soluble drug for oral or parenteral administration.Type: ApplicationFiled: November 10, 2009Publication date: September 1, 2011Applicant: Amorepacific CorporationInventors: Joon-Ho Bae, Hyeok Lee, Deok-Ki Hong, Jong-Hwi Lee
-
Publication number: 20110212994Abstract: Small molecule choline kinase inhibitors, pharmaceutical compositions thereof, and screening methods for identifying and evaluating choline kinase inhibitors are provided. Safe and effective methods for treating subjects suffering from a disorder or disease characterized by neoplastic cell proliferation employing the choline kinase inhibitors are also provided.Type: ApplicationFiled: June 28, 2010Publication date: September 1, 2011Inventors: BRIAN CLEM, SUCHETA TELANG, JOHN TRENT, JASON CHESNEY, POORAN CHAND, GILLES TAPOLSKY
-
Publication number: 20110201681Abstract: A cleansing bar composition comprising a soap; and a wax having a melting point of about 50° C. to about 75° C., sunflower oil, and myristyl myristate. In one embodiment, the wax is beeswax. The combination of the wax, the sunflower oil, and myristyl myristate allows for the deposition of a hydrophobic material to skin when in use.Type: ApplicationFiled: December 17, 2007Publication date: August 18, 2011Applicant: ColgatePalmolive CompanyInventor: Diana Scala
-
Publication number: 20110171308Abstract: A pH-sensitive solid pharmaceutical composition for oral formulation and preparation method thereof is provided. The solid pharmaceutical composition contains a pharmaceutical active ingredient, a nano-matrix carrier and a pH-sensitive polymer material.Type: ApplicationFiled: September 1, 2008Publication date: July 14, 2011Inventors: Qiang Zhang, Jiancheng Wang, Yulan Guo, Xuan Zhang, Zenggrong Jia, Ping Lin, Jinyang Zhang, Jie Zhang
-
Publication number: 20110165259Abstract: [Problem to be Solved] The purpose of present invention is to provide a medicine which has low contamination with a fine-pulverizing medium, is safe and has improved bioavailability. [Solution] A method for producing a composite organic compound powder for medical use is used which comprises: mixing a poorly water-soluble and crystalline organic compound powder, a physiologically acceptable salt, a physiologically acceptable polyol, and a carboxyvinyl polymer and fine-pulverizing the organic compound powder; and removing at least the salt and the polyol during or after fine-pulverizing.Type: ApplicationFiled: September 15, 2009Publication date: July 7, 2011Applicant: ACTIVUS PHARMA CO., LTD.Inventors: Takashi Hirokawa, Takahiro Tada, Jun Nihira
-
Publication number: 20110160274Abstract: The present invention provides a formulation of fenofibrate with enhanced oral bioavailability, simplicity of design and manufacture and absence of food effect. The formulation comprises fenofibrate dissolved in a lipophilic surfactant, with a hydrophilic surfactant optionally added. The formulation can be effectively used in the management and treatment of conditions such as hypertriglyceridemia, hypercholesterolemia and mixed dyslipidemia, and can also be effective at lower doses as compared to commercially available products. The invention additionally relates to the process of manufacture of the formulation and to dosage forms comprising the same.Type: ApplicationFiled: June 26, 2009Publication date: June 30, 2011Applicant: PANACEA BIOTEC LIMITEDInventors: Rajesh Jain, Sarabjit Singh, Naveen Jain, Shivanand Puthli
-
Publication number: 20110159082Abstract: The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables enhanced bioavailability of the active principle. The invention also concerns a method for preparing said composition without using any organic solvent.Type: ApplicationFiled: June 25, 2010Publication date: June 30, 2011Applicant: ETHYPHARMInventors: Bruno CRIERE, Pascal SUPLIE, Philippe CHENEVIER
-
Publication number: 20110152226Abstract: The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions.Type: ApplicationFiled: September 15, 2010Publication date: June 23, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Thomas S. Scanlan, Martin J. Kelly, Jian Qiu, Sandra Tobias, Oline K. Ronnekleiv
-
Publication number: 20110136888Abstract: The present invention involves substituted 1,3-diphenylpropane derivatives, pharmaceutical compositions comprising them and the therapeutic uses thereof, in particular in the fields of human and animal health.Type: ApplicationFiled: June 21, 2007Publication date: June 9, 2011Inventors: Jean-Francois Delhomel, Rémy Hanf, Karine Caumont-Bertrand
-
Publication number: 20110135764Abstract: Embodiments of the invention relate to a composition for controlling a target pest, wherein the composition includes at least two active ingredients selected from the group consisting of thymyl acetate, linalyl acetate, amyl butyrate, anise star oil, black seed oil, p-cymene, geraniol, isopropyl myristate, d-limonene, linalool, lilac flower oil, methyl salicylate, alpha-pinene, piperonal, piperonyl alcohol, tetrahydrolinalool, thyme oil white, thyme oil red, thymol, vanillin, and winter-green oil, wherein the composition causes synergistic control of the target pest.Type: ApplicationFiled: March 19, 2009Publication date: June 9, 2011Applicant: TyraTech, Inc.Inventor: Essam Enan
-
Publication number: 20110130448Abstract: The present invention relates to a compound of the formula: R-AR—O—Y—R? Wherein R represents one or more members selected from H, alkoxy, benzyloxy, aldehyde, halogen, carboxylic acid, —NO2, —NH2, —NHCOCH3, and —NH—Y—R?, which is attached directly to AR or attached through an aliphatic chain. The carboxylic acid moiety in R includes but is not limited to the following carboxylic acids: benzoic acids, cinnamic acids, ferulic acid, caffeic acid, syringic acid, salicyclic acid, vanillic acid, phenylacetic acids, phenylpropionic acids, and sinapinic acid. -AR—O— is a biologically active phenolic moiety comprising 1 to 6 substituted or unsubstituted aryl rings that are directly bonded to each other, fused together, or joined through a linking group.Type: ApplicationFiled: December 7, 2010Publication date: June 2, 2011Applicant: Bezwada Biomedical LLCInventor: Rao S. Bezwada
-
Publication number: 20110104291Abstract: The invention provides a method for manipulating or formulating a solid substance which melts under pressure of a gas without degrading at a temperature lower than the melting point of the substance at atmospheric pressure including: applying to the substance a liquefied gas or dense gas to melt the substance without degrading the substance; then contacting the molten substance with a carrier fluid, which is at substantially the same pressure as the liquefied gas or dense gas, to form a solution or mixture of at least a part of the molten substance and the carrier fluid; and passing the solution or mixture into a vessel of lower pressure than the pressure of the liquefied gas or dense gas and carrier fluid to form particles of the substance; and particles formed by the method.Type: ApplicationFiled: December 21, 2010Publication date: May 5, 2011Inventors: Neil Russell Foster, Hubert Leonardus Regtop, Fariba Dehghani, Andrian Tandya
-
Publication number: 20110097414Abstract: The present invention provides a pharmaceutical composition comprising adsorbate of fenofibrate or salt thereof or fenofibrate adsorbed on a pharmaceutically acceptable adsorbent and optionally one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of such compositions.Type: ApplicationFiled: February 26, 2008Publication date: April 28, 2011Inventors: Roshan lal Sandal, Vikrant Thakkar, Ramakant Kashinath Gundu, Rahul Sudhakar Dabre, Narayanan Murali, Girish Kumar Jain
-
Patent number: 7931917Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.Type: GrantFiled: May 23, 2007Date of Patent: April 26, 2011Assignees: Elan Pharma International, Ltd., Fournier Laboratories Ireland, Ltd.Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
-
Publication number: 20110092591Abstract: The present invention is related to a family of phenyl-prenyl derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the compounds of formula (I) for medical use, particularly for the use for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder, and to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.Type: ApplicationFiled: February 6, 2009Publication date: April 21, 2011Applicant: NOSCIRA S.A.Inventors: Javier Lopez Ogalla, Pilar Munoz Ruiz, Diana Alonso Gordillo, Miguel Medina Padilla, Esther Garcia Palomero, Ana Martinez Gil, Ana Castro Morera
-
Patent number: 7927627Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.Type: GrantFiled: May 23, 2007Date of Patent: April 19, 2011Assignees: Elan Pharma International, Ltd., Fournier Laboratories Ireland, Ltd.Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
-
Publication number: 20110059144Abstract: The present invention provides personal care compositions, as well as methods for protecting low viscosity hydrophobic liquid actives.Type: ApplicationFiled: January 13, 2009Publication date: March 10, 2011Inventors: Robert B. Fletcher, David L. Malotky, Xiaodong Zhang
-
Publication number: 20110059967Abstract: Compounds comprising Formula (I) or a pharmaceutically acceptable salt thereof, are disclosed, wherein J1, J2, U1, B, Y, and A are as described in claims 1-16. Methods, compositions, and medicaments related thereto are also disclosed, for treating glaucoma, inflammatory bowel disease and baldness.Type: ApplicationFiled: May 4, 2009Publication date: March 10, 2011Applicant: Allergan Inc.Inventors: David W. Old, Vinh X. Ngo
-
Publication number: 20110052682Abstract: Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipophilic carrier. The particles suspended in the hydrophilic or lipophilic carrier can be encapsulated in a hard or soft gelatin or non-gelatin capsule. It is believed that the microparticles produced by the method described above will exhibit enhanced dissolution profiles. In vitro release studies of formulations containing cilostazol and fenofibrate showed 100% dissolution of cilostazol in 15 minutes and over 90% dissolution of fenofibrate in 35 minutes.Type: ApplicationFiled: December 15, 2009Publication date: March 3, 2011Inventors: Aqeel Fatmi, Tae Kyoung Kim, Karla E. Madrigal
-
Publication number: 20110045069Abstract: A description is given of precursor compounds of sweet taste receptor antagonists for the prevention or treatment of disease, in particular for the prevention or treatment of Type 2 diabetes. A description is also given of uses of these precursor compounds and edible compositions, preparations for nutrition or pleasure or semi-finished products and pharmaceutical preparations, containing such precursor compounds.Type: ApplicationFiled: July 15, 2010Publication date: February 24, 2011Applicants: SYMRISE Gmbh Co. KG, Deutsches Institut für ErnährungsforschungInventors: Jakob Peter Ley, Michael Backes, Tobias Vössing, Frauke Stähler, Wolfgang Meyerhof, Christian Wintermeyer
-
Publication number: 20110034551Abstract: Methods for increasing sarcosine levels in a patient are provided. The methods include activating the PPAR? receptor. Increasing sarcosine levels can be used, for example, as part of a treatment for schizophrenia.Type: ApplicationFiled: September 18, 2008Publication date: February 10, 2011Applicant: BG MEDICINE, INC.Inventor: Robert Nicholas McBurney
-
Patent number: 7879907Abstract: Novel 3-phenylpropanoic acid compounds have the general formula (I) below: and are formulated into pharmaceutical compositions for administration in human or veterinary medicine (in dermatology, and also in the field of cardiovascular diseases, immune diseases and/or lipid metabolism-related diseases), or, alternatively, into cosmetic compositions.Type: GrantFiled: December 7, 2009Date of Patent: February 1, 2011Assignee: Galderma Research & DevelopmentInventors: Jean-Guy Boiteau, Laurence Clary, Jean-Claude Pascal, Veronique Parnet
-
Publication number: 20110020455Abstract: A powdery porous carrier comprising a porous silicon-containing carrier is impregnated with a solution containing an organic solvent and an active ingredient hardly soluble in water, and the organic solvent is removed to give a solid dispersion having the active ingredient supported to the porous carrier without a treatment with a supercritical fluid. The porous silicon-containing carrier has a heating loss of not more than 4% by weight at a temperature of 950° C. for 2 hours (e.g., a spherical silicon-containing carrier such as a spherical porous silica). The porous silicon-containing carrier may be a spherical silica having a mean pore size of 10 to 40 nm and an oil absorption of 175 to 500 ml/100 g. A pharmaceutical composition (e.g., tablets, granules, or capsules) may be prepared from the solid dispersion and a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 10, 2009Publication date: January 27, 2011Inventors: Kazushi Yoshida, Norimichi Okubo, Junichi Sakata, Hashime Kanazawa
-
Publication number: 20110015266Abstract: The present invention relates to a lyophilised nanoemulsion comprising a lipophilic phase and one or more sucrose fatty acid esters, to the nanoemulsion which can be prepared from the lyophilised nanoemulsion by redispersion, and to a process for the preparation of the lyophilised nanoemulsion.Type: ApplicationFiled: February 26, 2009Publication date: January 20, 2011Inventors: Andrea Hanefeld, Martina Schmidt, Simon Geissler, Peter Langguth
-
Publication number: 20110014176Abstract: This invention pertains to the discovery that certain extracts of licorice, particularly when formulated as a candy or lollipop or other means that provides an extended release (e.g., greater than about 4 minutes) to the oral cavity significantly inhibits the formation of dental caries in a human subject.Type: ApplicationFiled: March 13, 2009Publication date: January 20, 2011Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventors: James Dennen O'Neil, Michael K. Bamat, Reid W. von Borstel, Shalini Sharma, Ramachandran Arudchandran
-
Publication number: 20100323008Abstract: The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.Type: ApplicationFiled: December 18, 2009Publication date: December 23, 2010Applicant: LIFECYCLE PHARMA A/SInventors: Per Holm, Tomas Norling
-
Publication number: 20100310671Abstract: The present invention provides personal care compositions, as well as methods for protecting low viscosity hydrophobic liquid actives.Type: ApplicationFiled: November 12, 2008Publication date: December 9, 2010Inventors: David L. Malotky, Xiaodong Zhang
-
Publication number: 20100304966Abstract: Compounds of the formula I in which the substituents have the meaning given in the description, processes for preparing these compounds, compositions comprising them and their use for controlling harmful fungi.Type: ApplicationFiled: October 9, 2008Publication date: December 2, 2010Applicant: BASF SEInventors: Joachim Rheinheimer, Barbara Nave, Doris Kremzow, Stefan Redlich, Christian Pilger, Claudia Rosenbaum, Wassilios Grammenos
-
Publication number: 20100291201Abstract: Pharmaceutical compositions in unit dose form comprising a hard or soft capsule containing a fill consisting of one or more inert ingredients, and one or more coatings on the capsule, wherein at least one coating comprises at least one active pharmaceutical ingredient.Type: ApplicationFiled: May 14, 2009Publication date: November 18, 2010Applicant: CEROVENE, INC.Inventors: Manish S. SHAH, Ray J. Difalco
-
Publication number: 20100285126Abstract: The invention relates to pharmaceutical compositions comprising non-micronized fenofibrate with one or more pharmaceutically acceptable vehicles. The invention also relates to pharmaceutical compositions comprising non-micronized fenofibrate with one or more cyclodextrin derivatives. The invention also relates to processes for the preparation of such compositions.Type: ApplicationFiled: August 1, 2008Publication date: November 11, 2010Inventors: Rahul Dabre, Roshanlal Sandal, Vikrant Thakkar, Girish Kumar Jain
-
Publication number: 20100279971Abstract: This invention relates to compounds of the formula X) or XI) (X) (XI) wherein: each —R1, —R2 and —R3 is independently -Q1, —OH or —H, where at least one of —R1, —R2 and —R3 is not —H or —OH; each —R4 and —R5 is independently -Q2 or —H; each -Q1 is independently selected from: —F, —Cl, —RA, —ORA, —SH, —SRA, where each —RA is independently selected from methyl and ethyl, which may substituted by one or more fluoro or chloro groups; and each -Q2 is selected from: —F, —Cl, —RB, —ORB, —SH, —SRB, where each —RB is independently selected from methyl and ethyl, which may substituted by one or more fluoro or chloro groups; which are useful in the treatment of melanoma.Type: ApplicationFiled: December 18, 2008Publication date: November 4, 2010Inventors: Jose Neptuno Rodriguez-Lopez, Luis Sanchez Del Campo Ferrer, Juan Cabezas-Herrera, Alberto Tarraga Tomas, Magali Maria Saez Ayala
-
Patent number: 7816385Abstract: A novel class of dicarboxylic acid derivatives, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator -Activated Receptors (PPAR).Type: GrantFiled: December 12, 2003Date of Patent: October 19, 2010Assignee: High Point Pharmaceuticals, LLCInventors: Per Sauerberg, Lone Jeppesen, Zdenek Polivka, Karel Sindelar
-
Publication number: 20100260669Abstract: Multi-dose active agent packages and methods for using the same for treating a subject for a condition are provided. Aspects of the invention include a multi-dose active agent package containing a plurality of unit dosage forms of an active agent configured to modulate at least a portion of a subject's autonomic nervous system during at least one season of the year. The active agent is present in an amount sufficient to alter the parasympathetic activity/sympathetic activity ratio of the subject in a manner effective to treat the subject for the condition. The subject active agent packages and methods find use in the treatment of a variety of different conditions, including disease conditions that increase in severity and/or occurrence during one or more seasons of the year. Also provided are kits for use in practicing the subject methods.Type: ApplicationFiled: April 15, 2010Publication date: October 14, 2010Inventors: Anthony Joonkyoo Yun, Patrick Yuarn-Bor Lee
-
Publication number: 20100255095Abstract: The invention relates to pharmaceutical compositions comprising unmicronized fenofibrate in admixture with a wetting agent and one or more pharmaceutically acceptable excipients, wherein the admixture is not comicronized before processing. The invention also relates to processes for the preparation of such compositions.Type: ApplicationFiled: February 23, 2008Publication date: October 7, 2010Inventors: Ramakant Kashinath Gundu, Narayanan Murali, Girish Kumar Jain